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Abstract
Background: The reason why Cystic Fibrosis (CF) is the most common fatal genetic disease among Caucasians has
been incompletely studied. We aimed at deepening the hypothesis that CF carriers have a relative protection against
Mycobacterium tuberculosis (Mtb) infection.
Methods: Applying spatial epidemiology, we studied the link between CF carriership rate and tuberculosis (TB)
incidence in Brazil. We corrected for 5 potential environmental and 2 immunological confounders in this relation:
monthly income, sanitary provisions, literacy rates, racial composition and population density along with AIDS
incidence rates and diabetes mellitus type 2. Smoking data were incomplete and not available for analysis.
Results: A significant, negative correlation between CF carriership rate and TB incidence, independent of any of
the seven confounders was found.
Conclusion: We provide exploratory support for the hypothesis that carrying a single CFTR mutation arms against
Mtb infections.
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Background
In Europe, 1:20 to 1:80 people carry a mutation in the
Cystic Fibrosis Transmembrane Conductance Regulator
(CFTR) gene [1], rendering Cystic Fibrosis (CF) the most
common life-shortening autosomal recessive disorder
among Caucasians. Eighty-seven percent of European
patients with CF have at least one F508del allele [2], a
deletion of the phenylalanine (F) codon at position 508
[3] and supposed to be a founder mutation in Northern
Europe [4].
Thanks to a better understanding and treatment, the
mean life expectancy of patients with CF has increased
to over 30 years in developed countries nowadays. Until
the 1970s however, most CF patients died before reaching
reproductive age [5]. However, the reason why CF is still
as dominantly present, despite having an expected high
purifying index [6], remains unknown.
One hypothesis for this high CF carriership rate
among the Caucasian population could be that carrying
a single CF mutation has (had) an evolutionary selective
advantage. It has been suggested that CF heterozygotes
would be more resistant to cholera, typhoid fever or
tuberculosis. Using estimates of mortality from TB in
different regions, Poolman and Galvani [7] determined
that only Tuberculosis (TB) could account for modern-
day CF incidence rates in Euro-descendent populations.
They suggest that reduced susceptibility to TB in CF
heterozygotes could explain the modern gradient of CF in
Europe and around the globe, following the White Plague.
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We aimed at conducting an in-depth analysis of this pu-
tative link between CF mutations and TB and decided to
do so in Brazil. The country meets four conditions vital to
conduct meaningful research on this topic. First, 47•7% of
the population are Brasileiros brancos, or ‘white Brazilians’
of European descent [8]. This results in significant CF inci-
dence and carriership rate [9]. Second, Brazil is one of the
22 WHO-designated ‘high burden countries’ for TB [10].
Third, the dominant Brazilian Mycobacterium tuberculosis
(Mtb) strain is the same in Europe and the Americas [11].
Finally, elaborate datasets for CF and TB are available.
Given this unique context in Brazil, we analyse
whether support for the CF-TB hypothesis can be pro-
vided from a health geographical point of view. This is
done through a multidisciplinary, multiscalar spatial epi-
demiological study, addressing the question: ‘Are Caucasian
CF carriership rates in Brazil negatively associated with TB
incidence rates when corrected for confounders?’.
Methods
We researched the link between CF and TB on two scales
on the Brazilian territory: the state and municipality level.
Demographic data were extracted from the 2010 national
population census and 2014 population estimates [12].
The research was approved by the Institutional Ethics
Committees and registered through Plataforma Brasil.
At the state level, accurate F508del CFTR carriership
and TB data were available for six states: Bahia (BA),
Minas Gerais (MG), Rio de Janeiro (RJ), São Paulo (SP),
Paraná (PR) and Santa Catarina (SC) (Fig. 1).
Together, these states cover 116 million (m) inhabi-
tants (BA: 15•3 m, MG: 21•0 m, SP: 44•8 m, RJ:
16•7 m, PR: 11•3 m and SC: 6•9 m).
The research of Raskin et al. [13] for MG, SP, PR and
SC, Cabello et al. [14] for RJ, and Moura Costa et al.
[15] for BA provide the data on F508del carriership.
Information on the carriership frequency of other CFTR
mutations is not systematically reported. TB data per
state were obtained from the Health Ministry [16].
As it has been shown that big units of aggregation for
TB can lead to associations not being present at smaller
[17], a second, more detailed scale was defined: the
municipality level. São Paulo state’s 645 municipalities
were selected, as well-elaborated CF and TB registries
Fig. 1 Overview of the 6 Brazilian states included in this research
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exist for that state: the Brazilian Cystic Fibrosis Registry
(REBRAFC) [18] and the national Information System for
Notifiable Diseases – TB Registry (SINAN-TB) data-
bases respectively. Eight out of nine main CF Centres
of São Paulo State and the SINAN-TB registry ap-
proved the use of their anonymised data. For their
907 patients with CF registered in the REBRAFC, the
municipality of residence could be identified. SINAN-TB
comprises 155,317 registered TB cases in São Paulo state
between 2007 and 2014. Again, the patients’ municipality
of residence was retrieved.
Minimum CF mutation carriership for the munici-
palities was calculated multiplying CF prevalence by
two, as it is certain both parents of a patient with CF
are CFTR mutation carriers. The rareness of this
disease might cause unrealistically high incidence and
carriership rates if, for example, a single CF patient is
registered in a relatively sparsely populated municipality.
In order to exclude this ‘problem of the small numbers’,
only municipalities with over 10,000 inhabitants
were withheld.
We hypothesized that the diversity among municipal-
ities would allow correction for several external determi-
nants – potential confounders. Based on a study of the
human ecology of both CF and TB, we gathered munici-
pality data on five important environmental confounders:
the per capita nominal monthly income, sanitary provi-
sions, literacy rates, the racial composition of the popula-
tion and the population density [8]. We also studied
three comorbid risk factors that are known to impair the
immunological response to Mtb: AIDS incidence rates,
diabetes mellitus type 2 and smoking [19–21].
Subsequently, a cartographic analysis was performed
using GIS software (ArcMap10•2 by ESRI®). Maps were
produced for both levels, allowing visual interpretation
of the data. Positive spatial autocorrelation might occur
when rates of geographically close spatial areas are more
likely to be highly related than those from distant areas.
This was controlled for, guaranteeing a geographically
unbiased analysis at the municipality level.
Next, the municipality level findings were analysed
statistically using SPSS (IBM®) and SAS/STAT® software.
As data were not normally distributed, we calculated
Spearman correlation coefficients between incidence of
TB and prevalence of CF (bivariate level). Partial
Spearman rank correlations were adjusted for average
income, population density, literacy rates, share of
Caucasians, sanitary provisions, and AIDS incidence rates
(multivariate level). We also applied parametric tests by
use of linear regression models instead of Spearman rank
correlations to assure consistency in the results. For the
parametric tests, the TB incidence data were logarith-
mically transformed. A p-value ≤0•05 was considered
statistically significant for all tests.
Results
Using this multidisciplinary, multiscalar spatial epi-
demiological approach, we analysed whether Caucasian
CF carriership rates in Brazil negatively correlate with TB
incidence rates.
At the state-level, we analysed F508del carriership rates
versus TB incidence (Fig. 2). F508del carriership rates
were higher in states with a large share of Caucasians. In
the southernmost states for example, PR and SC, on
average 80% of inhabitants is considered to be Caucasian
[8]. The highest percentages of F508del CF mutation
carriers are also noted in those states.
Subsequently plotting F508del carriership against TB
incidence, showed a spatial pattern suggesting that states
with a higher share of F508del mutation carriers have
lower TB incidence rates. PR, SC and MG, while having
the highest percentage of carriers (2•38%, 1•79% and
1•37% respectively), are the states with the least TB
cases (21•0, 28•2 and 17•9 per 100,000 inhabitants). For
RJ, SP and BA, the opposite image is obtained. We
conclude to a cartographic trend. Given there are only
six observations at state level, carrying out a statistical
analysis is not useful.
Figure 3a shows the calculated municipal CFTR muta-
tion carriership rates on the municipal level. Figure 3b
shows the TB incidence rate for each respective munici-
pality. Again, an inverted pattern between CF mutation
carriership and TB incidence rates could be observed.
These cartographic observations were complemented
by statistical analyses. TB incidence rates were spatially
positively autocorrelated (Moran’s Index of 0•08, z-score
of 5•44 and p < 0•001). A Spearman correlation coeffi-
cient (r) was therefore calculated to quantify the CF-TB
relationship for the 171 municipalities with over 10,000
inhabitants in which at least one CF case has been regis-
tered (Fig. 4). In spite of the probable underestimation
of the number of CF carriers in each municipality, CF
carriership rate was significantly and inversely correlated
with TB incidence (r = −0•48 and p < 0•001). With
adjustments applied for monthly income, population
density, literacy rates, the racial composition of the
population, sanitary provisions and AIDS incidence rates
as partial variables, the corresponding partial Spearman
rank correlation was −0•39 (p < 0•001). Bivariate
analysis of TB or CF with diabetes mellitus type 2 as a
confounder was insignificant (p = 0.21 and p = 0.93
respectively). Data on smoking were not consistently
registered and hence unavailable for statistical analysis.
Subsequently, a multivariate analysis was run (Table 1),
showing that carriership rates correlate significantly
and inversely with log-transformed TB incidence
rates. This relation is independent of any of the five
potential environmental confounders identified and
AIDS incidence rates. Including diabetes mellitus data
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reduced the power of the overall model strongly so
was not used as an explanatory variable.
Discussion
This multidisciplinary, multiscalar study in Brazil is, to
our knowledge, the first to address the hitherto theoretical
link between CF carriership and TB incidence on a con-
temporary patient dataset. We found a significant, inverse
correlation between both, that remained valid after
thorough correction for potential environmental and im-
munological confounders.
Our approach is innovative as it highlights 3 additional
aspects to this hypothesis: 1. It extends the idea that
human genetics are an important factor in infectious
diseases; 2. It studies a possible evolutionary advantage
in a representative contemporary environment; 3. It
shows how health geography can contribute substantially
to elucidating a medical hypothesis.
First, the human genetics of infectious diseases para-
digm, the idea that a genetic defect can predispose to a
specific infectious pathogen, has revolutionized modern
medicine [22]. Increasingly, mutations and new genes
are being identified that render the host susceptible to a
specific pathogen [23]. Several genetic defects in the
defence against TB have been identified [24]. This allows
understanding why, whilst most TB-exposed individuals
only have latent disease, particular patients develop
fulminant TB disease (‘low disease burden’, ‘high suscep-
tibility’). Our research explores the same idea of a genetic
determinant in infectious disease. However, it changes the
question to why, despite having a high chance of developing
disease, some people have relative protection against the
Fig. 2 CF carriership prevalence and TB incidence for 6 Brazilian states. In states with a high carriership rate, TB incidence tends to be lower
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disease (‘high disease burden’, ‘low susceptibility’).
Important examples of already elaborated ‘resistance
genetics’ include sickle cell trait in survival advantage
against malaria [25] and the CCR5-delta32 mutation in
HIV resistance [26].
Yet, the field of ‘resistance genetics’ is still highly un-
explored. Brazil figures among the WHO listed 22 ‘high
burden’ countries for TB. At a municipality level, we
showed that the group of CF carriers did not have a lower
TB burden than other Brazilians [27]. Notwithstanding
this high burden, we found an inverse correlation between
CF carriership and TB incidence, suggesting a lower
susceptibility of CF carriers to TB infection.
Second, in both malaria and HIV, the geographic
spread of the ‘resistance allele’ led to the unravelling of
the link with its respective infectious disease. Also for
our research, the choice of an appropriate place has
proven crucial. Brazil is the only country worldwide that
combines high TB incidence with the European TB
strain and a high CF carriership background, making
Fig. 3 Map of the municipality-level data on the State of São Paulo for CF carriership prevalence (a) and TB incidence (b)
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statistical analyses possible. We were able to study
this large cohort thanks to access to the detailed
Brazilian registry for TB and CF. In this way evolu-
tionary genetics can be studied in a representative
contemporary environment.
Third, this study emphasizes the importance of a
multidisciplinary approach to evolutionary genetics. For
many years, the question why CF is so frequent amongst
Caucasians has been posed in medical literature, yet no
in-depth study has been undertaken to more definitively
answer this question. We show that Brazil’s geographical,
socio-economic and demographic diversity make it
possible to approach the role and impact of CFTR muta-
tions on TB infection, as well as of various external
determinants. This complexity could only be unravelled
by means of spatial analysis on medical registry data.
Now, the question goes back to the biomedical bench,
as only by cell biological research it will be possible to
elucidate and validate the molecular mechanisms behind
the found correlation. This biomedical validation is
essential to sustain this first preliminary evidence.
The multidisciplinary population-based approach of
our study covering 116 million Brazilian inhabitants is a
major strength, yet this method also implies several limi-
tations. First, the minimum CFTR mutation carriership
rates for the municipalities are only a proxy of the real
carriership frequency. As registry data were anonymized,
it cannot be excluded that siblings are counted as indi-
vidual patients, introducing an overestimation in the
number of carriers. Most probably, however, our data
are an underestimation of the CF carrier rate, as siblings
with a CFTR mutation have not been taken into account,
CF carriers not directly related to registered patients
could not be identified, and not all CF cases are diag-
nosed correctly. Brazil has recently initiated systematic
newborn screening for CF. As such, many CF cases that
Fig. 4 CF carriership versus TB incidence rates for the 171 Sao Paulo municipalities studied
Table 1 Multivariate statistical analysis on the municipality level
Variable [unit] Estimate Standard Error Probability > |t|
Intercept 2•3219 1•2420 0•06
Log (TB incidence rates) [Annual number of new TB cases/100,000 inhabitants] −0•2091 0•0843 a 0•0141
Average income
[Per capita Brazilian Real/Month]
−0•0002 0•0002 0•15
Population density [Inhabitants/km2] −0•0001 0•0000 b < 0•0001
Literacy rates [% of population] −0•0156 0•0149 0•21
Share of Caucasians
[% of population]
0•0050 0•0029 0•08
No sanitary provisions
[% of population]
0•0767 0•0355 a 0•0323
AIDS incidence rates [Incidence/100,000 inhabitants] 0•0023 0•0032 0•48
Results of the multivariate analysis of the correlation between CF carriership rates (number of CF carriers per 100,000 inhabitants) and TB incidence (annual
number of new TB cases per 100,000 inhabitants) correcting for six potential confounders
aindicates significant findings at the 0•05 significance level
bindicates significant findings at the 0•001 significance level
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would go unnoticed in countries without screening, are
now picked up. The frequency of CF disease has been
shown to be linked with carriership rate [28].
Next, the structure of both SINAN-TB and REBRAFC
registries limited the choice of aerial units that could
be chosen for the analyses. The municipality level was
the most detailed scale of research possible. Nevertheless,
this scale remains susceptible to ecological fallacy. To
address this limitation, a case-control study comparing
the CF carrier rate of individual Brazilian patients with
proven TB to age-, sex- and socio-economically matched
healthy individuals from the same municipality could be
envisaged. Future research could focus on the genetic
background of individual patients with TB.
Lastly, we could not study the link between carrying
CF and nontuberculous mycobacterial (NTMs) infec-
tion, as systematic municipality data on NTMs are
lacking. Primary immune deficiency (PID) patients with
Mendelian Susceptibility to Mycobacterial Disease
develop severe Mtb and NTM infections [29], and
patients with CF have a high susceptibility to infections
with NTMs [30]. It can therefore feel counterintuitive
that carrying one CFTR mutation would not result in
an increased but rather a reduced Mtb infection rate.
Yet Mtb and NTMs also differ importantly: they consti-
tute a distinct group within the Mycobacteria family
and have separate host traits, clinical features [31], and
drug resistance patterns [32]. Recent findings in PID
support that the immunological response to NTMs
might be different from that to Mtb [33].
Notwithstanding these limitations, we found indica-
tions for the relative protective role of carrying a single
CF mutation against infections with Mtb on two scales
on the Brazilian territory.
The possibility that CF carriership has (had) an evolu-
tionary advantage has been raised before. Candidate
agents of selective pressure for CF include cholera [34],
typhoid fever [35] and tuberculosis. Poolman and
Galvani computed that only the European tuberculosis
pandemic in the early 1600s can have provided sufficient
selective pressure to explain the modern CF incidence
[7]. On the other hand, it is also known that a mutation
in CFTR cannot be fully protective against Mtb
infection, as cases of patients with CF and TB have been
reported [36].
Never before however, a study has addressed this
theoretical hypothesis with patient data.
This observation is relevant, as a rationale for the
high CF incidence in Euro-descendants could now be
provided. Equally, once a potential human protection
mechanism against Mtb infection can be uncovered,
this opens up opportunities for the development of
new treatment strategies against the disease and
implies a vital step towards eradicating TB worldwide.
Conclusions
Using a multidisciplinary, multiscalar spatial epidemio-
logical approach, we found exploratory support for the
hypothesis that carrying a single CF mutation plays a
relative protective role against Mtb infections. This
could provide a rationale for the continued CF occur-
rence and encourages biomedical research into the
human resistance genetics of tuberculosis and by exten-
sion other infectious diseases.
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